APA (7th ed.) Citation

A, B., D, D., M, G., C, J., J, B., M, S., & CS, S. (2022). Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland. BMC health services research, 22(1), 837. https://doi.org/10.1186/s12913-022-08211-y

Chicago Style (17th ed.) Citation

A, Bhadhuri, Dröschel D, Guldimann M, Jetschgo C, Banhazi J, Schwenkglenks M, and Sutherland CS. "Cost-effectiveness of Voretigene Neparvovec in the Treatment of Patients with Inherited Retinal Disease with RPE65 Mutation in Switzerland." BMC Health Services Research 22, no. 1 (2022): 837. https://doi.org/10.1186/s12913-022-08211-y.

MLA (9th ed.) Citation

A, Bhadhuri, et al. "Cost-effectiveness of Voretigene Neparvovec in the Treatment of Patients with Inherited Retinal Disease with RPE65 Mutation in Switzerland." BMC Health Services Research, vol. 22, no. 1, 2022, p. 837, https://doi.org/10.1186/s12913-022-08211-y.